Spots Global Cancer Trial Database for liver carcinoma
Every month we try and update this database with for liver carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery | NCT04955808 | Breast Carcinom... Colon Carcinoma Invasive Carcin... Kidney Carcinom... Liver Carcinoma Malignant Solid... Multiple Myelom... Prostate Carcin... | Biospecimen Col... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Liver Transplantation for Unresectable GIST Liver Metastases | NCT04825470 | Liver Diseases Liver Cancer Liver Metastase... Liver Neoplasms Liver Mass Liver Carcinoma Liver Transplan... Liver Transplan... GIST GIST, Malignant Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Metastases to L... Metastatic Live... Metastasis Metastases Liver Transplan... Transplant Onco... | Liver Transplan... | 18 Years - | Hospital Universitario Virgen de la Arrixaca | |
| Liver Transplantation for Unresectable GIST Liver Metastases | NCT04825470 | Liver Diseases Liver Cancer Liver Metastase... Liver Neoplasms Liver Mass Liver Carcinoma Liver Transplan... Liver Transplan... GIST GIST, Malignant Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Metastases to L... Metastatic Live... Metastasis Metastases Liver Transplan... Transplant Onco... | Liver Transplan... | 18 Years - | Hospital Universitario Virgen de la Arrixaca | |
| The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma | NCT01380392 | Liver Carcinoma | 20 Years - | National Taiwan University Hospital | ||
| Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma | NCT00791544 | Liver Carcinoma | AVE1642 sorafenib erlotinib | 18 Years - | Sanofi | |
| Hepatocellular Carcinoma Treated With Iodine-125 Implantation | NCT01717729 | Liver Carcinoma | Radiofrequency ... iodine | 18 Years - 75 Years | The Second People's Hospital of GuangDong Province | |
| Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial | NCT01272557 | Liver Carcinoma | Doxorubicin Sorafenib | 18 Years - | Martin-Luther-Universität Halle-Wittenberg | |
| A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | NCT06144385 | Liver Carcinoma Hepatic Cell Ca... | CAR-GPC3 T cell... | 18 Years - 75 Years | Shanghai Ming Ju Biotechnology Co., Ltd. | |
| Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma | NCT00791544 | Liver Carcinoma | AVE1642 sorafenib erlotinib | 18 Years - | Sanofi | |
| Hepatocellular Carcinoma Treated With Iodine-125 Implantation | NCT01717729 | Liver Carcinoma | Radiofrequency ... iodine | 18 Years - 75 Years | The Second People's Hospital of GuangDong Province | |
| Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis | NCT04288323 | Liver Cancer Liver Cirrhoses Liver Carcinoma | Gadolinium etho... | 18 Years - | University of California, San Diego | |
| Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery | NCT04955808 | Breast Carcinom... Colon Carcinoma Invasive Carcin... Kidney Carcinom... Liver Carcinoma Malignant Solid... Multiple Myelom... Prostate Carcin... | Biospecimen Col... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation | NCT01744639 | Liver Carcinoma | HCC under treat... | 18 Years - 65 Years | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | |
| Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) | NCT04443322 | Liver Carcinoma Liver Transplan... | Durvalumab Inje... Lenvatinib 4 MG | 18 Years - 80 Years | RenJi Hospital | |
| The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma | NCT01380392 | Liver Carcinoma | 20 Years - | National Taiwan University Hospital | ||
| De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma | NCT00328770 | Liver Carcinoma | Sirolimus | 18 Years - 70 Years | University of Alberta | |
| AFP Model and Liver Transplantation. | NCT03775863 | Liver Carcinoma Liver Transplan... | Liver transplan... | - | Austral University, Argentina | |
| De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma | NCT00328770 | Liver Carcinoma | Sirolimus | 18 Years - 70 Years | University of Alberta | |
| Combined HCC-MFCCC | NCT03178409 | Liver Carcinoma Hepatocellular ... Cholangiocarcin... Surgery | Hepatectomy | 18 Years - | University of Milan | |
| Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation | NCT01744639 | Liver Carcinoma | HCC under treat... | 18 Years - 65 Years | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | |
| CIRSE Registry for SIR-Spheres Therapy | NCT02305459 | Liver Carcinoma | Yttrium-90 load... QLQ-C30 with HC... | 18 Years - | Cardiovascular and Interventional Radiological Society of Europe | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma | NCT00328770 | Liver Carcinoma | Sirolimus | 18 Years - 70 Years | University of Alberta | |
| SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma | NCT01482442 | Liver Carcinoma | sorafenib SIR-Sphere | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial | NCT01272557 | Liver Carcinoma | Doxorubicin Sorafenib | 18 Years - | Martin-Luther-Universität Halle-Wittenberg | |
| SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma | NCT01482442 | Liver Carcinoma | sorafenib SIR-Sphere | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| AFP Model and Liver Transplantation. | NCT03775863 | Liver Carcinoma Liver Transplan... | Liver transplan... | - | Austral University, Argentina | |
| A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | NCT06144385 | Liver Carcinoma Hepatic Cell Ca... | CAR-GPC3 T cell... | 18 Years - 75 Years | Shanghai Ming Ju Biotechnology Co., Ltd. | |
| Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis | NCT04288323 | Liver Cancer Liver Cirrhoses Liver Carcinoma | Gadolinium etho... | 18 Years - | University of California, San Diego | |
| Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) | NCT04443322 | Liver Carcinoma Liver Transplan... | Durvalumab Inje... Lenvatinib 4 MG | 18 Years - 80 Years | RenJi Hospital | |
| Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers | NCT04682847 | Liver Neoplasms Hepatic Cirrhos... Hepatic Carcino... Liver Cancer Liver Metastase... Liver Carcinoma Hepatocellular ... Hepatocellular ... Hepatic Atrophy | Ferumoxytol inj... | 18 Years - 89 Years | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | |
| Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden | NCT00960557 | Neoplasm Metast... | Combretastatin ... | 18 Years - | Mateon Therapeutics | |
| Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma | NCT05681234 | Liver Carcinoma | 18F-RD2 | 18 Years - | Affiliated Hospital of Jiangnan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
